OTX008 is primarily investigated for its potential in cancer therapy. It functions as a galectin-1 inhibitor, targeting the protein involved in tumor growth and angiogenesis. By disrupting galectin-1, OTX008 aims to inhibit the formation of new blood vessels that supply tumors, thereby limiting their growth and metastasis. This makes it a promising candidate for treating various cancers, particularly those resistant to conventional therapies. Research is ongoing to explore its efficacy in preclinical models, with a focus on its ability to enhance the effectiveness of existing treatments and improve patient outcomes.